Marie Gårdmark: “What to expect from Trump’s second term?”

One may complain about the complex multinational system in EU, but it gives us some predictability that cannot be easily overturned by different member states p...

Skrubben bakom Nobelprisupptäckten

Det hör inte till vanligheterna att upptäckter som leder till Nobelpris görs på små biotechbolag. Ännu mer sällsynt är att arbetet bakom den prisbelönta forskni...

FDA approves first non-opioid pain reliever in over 20 years

For the first time in decades, a new type of acute pain medication that is not an opioid has been approved in the USA.

Smart kommunikation i processindustrin – HART-teknik som ger full kontroll

Med HART-teknik får du mer än bara ett mätvärde. Du får en kommunikationslänk som öppnar för avancerad information direkt från fältinstrumenten – utan extra kab...

Who pays for Rebecca Doe – and all of us?

Anna Törner on how easily we get used to the idea that healthcare is free - when it really is about how and who pays for it

Explore the latest trends and innovations in quality assurance and manufacturing

ZEISS QUALITY INNOVATION SUMMIT in Berlin, October 22-24, 2024.

The future of healthcare in focus: ”Together, things happen”

In march, it’s once again time for Fokus Patient, an event for the industry where the patients’ perspective takes center stage. It’s a great way to spread knowl...

Proaktiv övervakning och läckagetest av värmeväxlare

Maximera drifttid och resursutnyttjande i produktionen.

Pneumatics Makes a Technological Leap with Piezo

The first high-precision proportional valve terminal VTEP opens up new application areas

New Insights into Microscopy

Watch the recording of our free webinar.

New cell therapy raises hope for curing type 1 diabetes – "Never succeeded before"

For the first time, a patient with type 1 diabetes has undergone an islet transplantation using genetically modified insulin-producing cells that do not require...

New Horizons in Biologics & Bioprocessing incl. Advanced Therapies: Stockholm (2026)

Allogene discontinues investigational antibody following patient death

U.S. biotechnology company Allogene Therapeutics is fully discontinuing the use of its experimental antibody ALLO-647 following the death of a patient in its pi...

Neogap värvar tungt namn inom cellterapi

Bioteknikbolaget Neogap Therapeutics fyller på styrelsen med expertis inom cellterapi i form av professor Jonas Mattsson.

Cost-efficient development of laboratory devices

8 ways to optimise development costs and speed up processes

Cancer dominerar svenska läkemedelsprövningar – här är andra heta områden

För första gången finns en nationell och samlad bild av de läkemedelsprövningar som pågår i Sverige. Den visar att onkologi är klart dominerande, men också att ...

Government apoints new experts to medicine and health council

Johanna Fälting, Head of Research at BioArctic, and physician Markus Lingman have been appointed as new members of the Swedish Research Council’s Subject Counci...

“Life science is important on a personal level”

From the High Coast to the Government Offices. Jeanette Edblad is a native of Ångermanland, and since September last year, she has been Head and Coordinator of ...

Anna Törner: ”If I fall seriously ill, I’ll move to Finland”

”It is both undignified and undemocratic that cancer patients must travel to Finland to uphold a façade of fairness that does not truly exist”, Anna Törner writes in a column.

GSK acquires oncology research company

GSK acquires the American biotechnology company Idrx for up to 1.15 billion dollars.

Lund University’s record-breaking recruitment – attracting researchers from around the world

The Swedish university is launching its largest international recruitment effort ever, aiming to hire 25 researchers globally, including several in the medical field.

Improved processes and more

Discover the full potential and benefits.

Mercodia AB

”Information security must become part of the Swedish life science strategy”

Sweden needs knowledge security to stand strong in the global competition, writes Björn Ursing in an opinion article.